- Home
- CGNT vs PLRX Comparison
CGNT vs PLRX Comparison
Compare CGNT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- PLRX
- Stock Information
- Founded
- CGNT 2020
- PLRX 2015
- Country
- CGNT Israel
- PLRX United States
- Employees
- CGNT N/A
- PLRX N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- PLRX Health Care
- Exchange
- CGNT Nasdaq
- PLRX Nasdaq
- Market Cap
- CGNT 639.4M
- PLRX 641.5M
- IPO Year
- CGNT N/A
- PLRX 2020
- Fundamental
- Price
- CGNT $8.51
- PLRX $11.77
- Analyst Decision
- CGNT Hold
- PLRX Strong Buy
- Analyst Count
- CGNT 3
- PLRX 7
- Target Price
- CGNT $8.25
- PLRX $40.50
- AVG Volume (30 Days)
- CGNT 242.6K
- PLRX 544.4K
- Earning Date
- CGNT 12-11-2024
- PLRX 02-26-2025
- Dividend Yield
- CGNT N/A
- PLRX N/A
- EPS Growth
- CGNT N/A
- PLRX N/A
- EPS
- CGNT N/A
- PLRX N/A
- Revenue
- CGNT $339,818,000.00
- PLRX N/A
- Revenue This Year
- CGNT $13.30
- PLRX N/A
- Revenue Next Year
- CGNT $7.28
- PLRX N/A
- P/E Ratio
- CGNT N/A
- PLRX N/A
- Revenue Growth
- CGNT 12.16
- PLRX N/A
- 52 Week Low
- CGNT $5.44
- PLRX $10.22
- 52 Week High
- CGNT $9.59
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- CGNT 48.66
- PLRX 34.86
- Support Level
- CGNT $8.62
- PLRX $12.40
- Resistance Level
- CGNT $9.05
- PLRX $13.71
- Average True Range (ATR)
- CGNT 0.24
- PLRX 0.76
- MACD
- CGNT -0.07
- PLRX -0.17
- Stochastic Oscillator
- CGNT 11.48
- PLRX 18.66
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.